We are live on
!
Find out more
DAWN
Day One Biopharmaceuticals
DAWN
DAWN
Delisted
DAWN was delisted on the 22nd of April, 2026.
206 hedge funds and large institutions have $1.85B invested in Day One Biopharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 83 funds opening new positions, 61 increasing their positions, 47 reducing their positions, and 57 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
13% more funds holding
Funds holding: 183 → 206 (+23)
4.75% more ownership
Funds ownership: 79.29% → 84.04% (+4.8%)
20% less call options, than puts
Call options by funds: $37.8M | Put options by funds: $47.4M
Holders
206
Holding in Top 10
6
Calls
$37.8M
Puts
$47.4M
Top Buyers
| 1 | +$66M | |
| 2 | +$58.2M | |
| 3 | +$54.9M | |
| 4 |
JP Morgan Chase
New York
|
+$43.6M |
| 5 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$34.7M |
Top Sellers
| 1 | -$80.2M | |
| 2 | -$59.8M | |
| 3 | -$48.5M | |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$42M |
| 5 |
BlackRock
New York
|
-$25.3M |
